نتائج البحث - "Dutcus, Corina E"

المساهمون: This study was supported by Eisai, Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

المصدر: British Journal of Cancer ; volume 124, issue 1, page 237-246 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-020-01092-0Test
https://www.nature.com/articles/s41416-020-01092-0.pdfTest
https://www.nature.com/articles/s41416-020-01092-0Test

View record in BASE

5

دورية أكاديمية

Second-line lenvatinib in patients with recurrent endometrial cancer

المؤلفون: Vergote, Ignace, Powell, Matthew A., Teneriello, Michael G., Miller, David S., Garcia, Agustin A., Mikheeva, Olga N., Bidzinski, Mariusz, Cebotaru, Cristina Ligia, Dutcus, Corina E., Ren, Min, Kadowaki, Tadashi, Funahashi, Yasuhiro, Penson, Richard T.

المساهمون: Eisai Inc., Merck Sharp & Dohme Corp.

المصدر: Gynecologic Oncology ; volume 156, issue 3, page 575-582 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2019.12.039Test
https://api.elsevier.com/content/article/PII:S0090825819318694?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825819318694?httpAccept=text/plainTest

View record in BASE

6

دورية أكاديمية

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

المؤلفون: Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.

المساهمون: Eisai Inc., Woodcliff Lake, NJ, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

المصدر: British Journal of Cancer ; volume 121, issue 3, page 218-221 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-019-0506-6Test
http://www.nature.com/articles/s41416-019-0506-6.pdfTest
http://www.nature.com/articles/s41416-019-0506-6Test

View record in BASE

7

دورية أكاديمية

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

المؤلفون: Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.

المصدر: British Journal of Cancer ; volume 121, issue 7, page 625-625 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-019-0534-2Test
http://www.nature.com/articles/s41416-019-0534-2.pdfTest
http://www.nature.com/articles/s41416-019-0534-2Test

View record in BASE

8

دورية أكاديمية

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma

المؤلفون: Hida, Toyoaki, Velcheti, Vamsidhar, Reckamp, Karen L., Nokihara, Hiroshi, Sachdev, Pallavi, Kubota, Tomoki, Nakada, Takuya, Dutcus, Corina E., Ren, Min, Tamura, Tomohide

المساهمون: Eisai Inc., Woodcliff Lake, NJ, USA, Merck & Co., Inc., Kenilworth, NJ, USA

المصدر: Lung Cancer ; volume 138, page 124-130 ; ISSN 0169-5002

مصطلحات موضوعية: Cancer Research, Pulmonary and Respiratory Medicine, Oncology

الإتاحة: https://doi.org/10.1016/j.lungcan.2019.09.011Test
https://api.elsevier.com/content/article/PII:S0169500219306555?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0169500219306555?httpAccept=text/plainTest

View record in BASE

9

دورية أكاديمية

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer

المؤلفون: Tahara, Makoto, Brose, Marcia S., Wirth, Lori J., Suzuki, Takuya, Miyagishi, Hideaki, Fujino, Katsuki, Dutcus, Corina E., Gianoukakis, Andrew

المساهمون: Eisai Inc, Oxford PharmaGenesis Inc

المصدر: European Journal of Cancer ; volume 106, page 61-68 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.ejca.2018.10.002Test
https://api.elsevier.com/content/article/PII:S0959804918314308?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0959804918314308?httpAccept=text/plainTest

View record in BASE

10

دورية أكاديمية

Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid

المؤلفون: Tahara, Makoto, Schlumberger, Martin, ELISEI, ROSSELLA, Habra, Mouhammed Amir, Kiyota, Naomi, Paschke, Ralf, Dutcus, Corina E., Hihara, Taro, Mcgrath, Shannon, Matijevic, Mark, Kadowaki, Tadashi, Funahashi, Yasuhiro, Sherman, Steven I.

المساهمون: Tahara, Makoto, Schlumberger, Martin, Elisei, Rossella, Habra, Mouhammed Amir, Kiyota, Naomi, Paschke, Ralf, Dutcus, Corina E., Hihara, Taro, Mcgrath, Shannon, Matijevic, Mark, Kadowaki, Tadashi, Funahashi, Yasuhiro, Sherman, Steven I.

مصطلحات موضوعية: Biomarker, Clinical trial, Lenvatinib, Phase 3, Thyroid cancer, Tyrosine kinase inhibitor, Oncology, Cancer Research

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28237867; info:eu-repo/semantics/altIdentifier/wos/WOS:000399856400028; volume:75; firstpage:213; lastpage:221; numberofpages:9; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11568/850508Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85013655871; https://www.sciencedirect.com/science/article/pii/S0959804917300709Test

الإتاحة: https://doi.org/10.1016/j.ejca.2017.01.013Test
http://hdl.handle.net/11568/850508Test
https://www.sciencedirect.com/science/article/pii/S0959804917300709Test

View record in BASE

تنقيح النتائج